HOME >> BIOLOGY >> NEWS
Ribozyme Pharmaceuticals, Inc. Demonstrates Potent Activity Of A Ribozyme Targeted Against The Hepatitis C Virus

Presented at Amer. Assoc. for the Study of Liver Diseases Conference

BOULDER, Colorado, November 9, 1998 -- Ribozyme Pharmaceuticals, Inc. (RPI) (Nasdaq: RZYM) today announced that HEPTAZYME®, a ribozyme designed to selectively destroy Hepatitis C Virus (HCV) RNA, was effective in decreasing Hepatitis C Viral RNA in cell culture assays. This work was presented at the American Association for the Study of Liver Diseases (AASLD) conference in Chicago by Dr. Lawrence Blatt, RPI's Senior Director of Biopharmacology and Preclinical Research. In these studies, HEPTAZYME® demonstrated significant inhibition of the HCV viral translation process in cells at very low doses, and in a manner that implies applicability across multiple forms of the virus.

Hepatitis C Virus (HCV) is the most common chronic bloodborne infection in the United States today. A recent Centers for Disease Control report stated that over 4 million Americans are chronically infected with HCV, and it is estimated that 500 million people are infected with HCV worldwide. The disease, which is more common than HIV, kills 8,000-10,000 Americans annually, and the death toll is expected to triple over the next 10-20 years. Furthermore, development of effective treatments has been hampered by the presence of multiple forms of HCV, with at least six genotypes and more than 90 subtypes known.

HEPTAZYME® contains many novel features believed to be important for HCV treatment. First, HEPTAZYME® is a ribozyme, a catalytic RNA molecule that has the unique potential to bind and cleave HCV RNA specifically and selectively, thus suggesting that viral replication can be inhibited without affecting other normal physiological processes. Next, HEPTAZYME® cleaves the HCV RNA at a location that is completely conserved in all known genotypes and subtypes of HCV, which gives HEPTAZYME® the potential to inhibit all forms of the virus. Finally, since HCV replicates in the cytoplas
'"/>

Contact: Neil Cohen
neil@noonanrusso.com
415-677-4455 x. 205
Noonan/Russo Communications
9-Nov-1998


Page: 1 2 3

Related biology news :

1. Ribozyme package effective against hepatitis B virus
2. Ribozymes Come Ready For Action
3. Ribozymes To The Rescue: New UF Gene Therapy Shows Promise For Treatment Of Inherited Blindness
4. Interdisciplinary Method Offers New Way To Study Ribozymes
5. Vion Demonstrates Readiness Of First Tumor-Targeting Salmonella For Human Testing Against Solid Tumors
6. Engineering Animation, Inc. Demonstrates Internet Anatomy At Visible Human Project Conference
7. Study Demonstrates High Conservation Potential Of Logged Rainforest
8. Potential for enhanced sequestration of carbon in soils supports evaluations
9. Potent toxin reveals new antibiotic resistance mechanism
10. Potential blood test for colon cancer risk
11. Potential new treatment for Gaucher disease developed by scientists at Scripps Research Institute

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/14/2018)... ... 13, 2018 , ... Career fairs provide an ideal setting ... systems at once. However, healthcare professionals often have hectic schedules with little spare ... healthcare providers who wish to explore opportunities and learn about multiple employers from ...
(Date:8/14/2018)... , ... August 13, 2018 , ... ... products, the Staticmaster® P-2021-5502 and P-2021-5602 Cleanroom Ionizing Gun. , The ionizing ... Nitrogen Air Gun, P-2021 ionizing cartridge, 0.5-micron filter and electropolished OSHA-compliant tip. This ...
(Date:8/14/2018)... Fla. (PRWEB) , ... August 14, 2018 , ... ... activity and sleep monitoring solutions for the global scientific community, announced today the ... focus of this new division is to foster and support scientific collaborations with ...
Breaking Biology News(10 mins):
(Date:8/9/2018)... ... August 08, 2018 , ... InTouchMD , the ... announced that they will be exhibiting at Biotech Week Boston , September 4th ... showcasing its Pulse platform, healthcare’s most powerful all in one marketing solution. ...
(Date:8/7/2018)... ... August 06, 2018 , ... Slone Partners, North America’s ... of Dr. Paul Harney as President, North America at Prescient Healthcare Group. Dr. ... client satisfaction. He was also named to Prescient’s Board of Directors. , ...
(Date:7/31/2018)... ... July 31, 2018 , ... ... years, announces the launch of their new website. The new website has been ... the site. Mahoney partnered with Proceed Innovative to build a website created for ...
(Date:7/25/2018)... MATEO, Calif. (PRWEB) , ... July 25, 2018 ... ... for in vivo research utilizing its state-of-the-art Digital Vivarium™ and Vium Cloud approach ... Schaevitz, Ph.D., to Chief Scientific Officer. Additionally, the company announced the appointment of ...
Breaking Biology Technology:
Cached News: